30.01.2021, 4:00pm
Next news >< Previous news
Most Successful Exit in the History of High-Tech Gründerfonds – Gilead Sciences to Acquire MYR GmbH

MYR is the first private German biotech company to successfully take a drug from preclinical development to market. US pharmaceutical company Gilead Sciences is set to acquire MYR for roughly EUR 1.15 billion.
Platin Sponsors
Gold Sponsors
Silver Sponsors
Supporters
Media Partners
Bilateral Talks
- Participants342
- Meetings Requested2449
- Meetings Accepted1242
Participants
-
Austria 5
-
Belgium 15
-
Brazil 1
-
Chile 1
-
China 5
-
Denmark 3
-
England 1
-
Finland 3
-
France 11
-
Germany 252
-
India 1
-
Israel 2
-
Italy 3
-
Kenya 1
-
Latvia 3
-
Luxembourg 1
-
Netherlands 29
-
Norway 2
-
Oman 2
-
Poland 2
-
Portugal 4
-
Singapore 4
-
Slovenia 1
-
South Korea 2
-
Spain 5
-
Sweden 2
-
Switzerland 7
-
United Kingdom 5
-
USA 7
-
Venezuela 1
- Total of Participants381